This is a specially commissioned editorial from the Graphene Flagship Work Package on Health and Environment. This editorial is part of the 2D Materials focus collection on 'Progress on the science and applications of two-dimensional materials', published in association with the Graphene Flagship. It provides an overview of key, recent advances from the 'Health and Environment' work package and is not intended as a comprehensive review of this field.
Graphene and two-dimensional (2D)-related materials are heavily permeating the market of electronics, optoelectronics, photonics, material composites, and to a more limited extent, the field of biomedicine [1] . The proper assessment of the safety profile and the impact of such nanomaterials on health and environment is a fundamental prerequisite to translate any development into action, from industrial applications to health care perspectives. In this context, graphenerelated materials have been recently listed as having a potential significant impact on human health and on the environment [2] . At the end of 2014, the Scientific Committee on Emerging and Newly Identified Health Risks has acknowledged graphene nanomaterials in the hazard category, asking for urgent estimation of the risks, as there are many gaps to be filled [2]. The Flagship program of the work package on Health and Environment, described in the ramp-up map [1] , has anticipated the alarm of the authorities proposing to thoroughly explore the risks associated with the release of graphene-related materials in the future. A proactive action is currently undertaken in the Flagship, aimed at proving the safety profile of graphene-related materials and to offers solution in case of identified risks [3] .
Based on the available results reported in the literature, graphene-related materials are not devoid of possible risks on human health or on the environment. Little is still known about their emissions, the fate in the environment and the toxic effects in humans. It might be possible that, in the long run, these materials may have potentially adverse environmental effects or pose health risks [4] . Humans can be exposed to graphene and related materials by different routes, such as inhalation, skin contact, ingestion or even direct injection or implantation through novel biomedical therapies [5] . Some graphene-related materials are produced as dry powders using thermal exfoliation, and in these cases, inhalation and skin absorption are likely routes of human exposure [3] . It has been shown that certain grapheme materials have aerodynamic sizes that can lead to inhalation and subsequent significant accumulation in the human respiratory tract [6] . In light of the current studies, the picture is still controversial. Part of these studies show that there are no specific risks related to the use of graphene-related materials; conversely, other investigations have evidenced that some forms of graphene might become a health hazard [7, 8] . On the other hand, the biological effects and responses to accidental exposure can differ depending on physicochemical properties (i.e. number of layers, lateral size, stiffness, hydrophobicity, and surface functionalization), together with the degree of purity of graphene materials or the administered dose. Limited data are still available on the difference in biological behavior between large (few micron lateral size) and small (few hundred nanometer lateral size) sheets of graphene, or single-layer graphene versus few-layer graphene [9] .
One concern we address in the Flagship project is that graphene includes a variety of forms that render it difficult to rationalize the data on the toxicity effects. In our vision, a strong prerequisite of any community approaching the study of nanomaterials toxicity by means of inter-and multidisciplinary approaches is the sharing of a 'classification approach' for the nanomaterial itself, including graphene-related materials. To partly address this problem, we have proposed a classification strategy that takes into account three parameters necessary to identify the different graphene materials: (i) the average lateral dimension of the flakes; (ii) the number of layers; and (iii) the amount of oxygenated groups, which transform graphene, originally hydrophobic, into a hydrophilic form (graphene oxide). The latter is particularly relevant since graphene oxide is widely exploited in many fields, due to the ease of scaled-up (multi-kilogram) production. Our proposed classification framework allows the unambiguous definition of the graphene forms under consideration, based on the three easyto-measure and quantifiable material characteristics listed above [9] . Such methodology can, and probably will, be validated by biologists and nanotoxicologists working with graphene and other benchmarked carbon materials.
An initial attempt to use our classification to understand the structure-function relationship between the effects and the physicochemical characteristics of graphene materials has been very recently reported [10] . The analysis of 34 articles on preclinical in vivo studies using different graphene forms has highlighted that the lung is the organ with the highest risk of damage. The high accumulation of graphene materials with lateral size larger than 100 nm into pulmonary tissues is independent of the administration routes, mainly leading to inflammatory responses. Most of the screened articles were aimed at developing graphene materials for biomedical applications and explore systemic administrations. Most relevant routes to hazard assessment in the context of occupational health and environmental protection, such as inhalation, ingestion and skin contact, have instead been explored very little. A major flaw in all these studies is that no one has used samples that only contain one single layer of graphene. This is certainly due to the intrinsic difficulties of producing stable colloidal suspensions of single-layer graphene, even though stabilization with biocompatible surfactants is possible. As part of the project in the work package Health and Environment, we address this critical issue by developing a method to obtain highly stable graphene dispersions in water. It is of fundamental importance for the biological and toxicological tests to have a material devoid of possible contaminations, due to the presence of organic solvents and non-biocompatible surfactants [11] .
In relation to these issues, in our ramp-up programm, we cover a series of specific and closely interconnected goals. Being fully aware of the 'graphene safety landscape' that has led to inconclusive results so far, we mainly focus on few-layer graphene dispersed in water and graphene oxide (GO) provided by partners of the Flagship. With a precise description of the material, the correlation between the physicochemical features and the biological effects will be facilitated. We have started to elucidate the mechanisms of how the selected materials interact with cells and their barriers. We address the effects of these types of graphene on specific cells and tissues, such as the immune system, nervous system, and gastro-intestinal tract, and to determine inflammatory responses and biomarkers for possible pathogenic risks. We have started to study the biodegradation of GO by specific intracellular peroxidases. In a very recent publication, we have highlighted the role of hydrophilicity, negative surface charge and colloidal stability of aqueous GO in its biodegradation process [12] . We have assessed the importance of the material properties, such as the state of aggregation and surface functionalities. We have discovered that water dispersibility remarkably affects the capacity of myeloperoxidase, an enzyme present in neutrophils, to degrade different types of GO. This enzyme is capable of completely metabolizing highly dispersed GO, while it failed in degrading the most highly aggregated GO. On the basis of these results, we suggest that highly stable colloidal suspension of graphene oxide may pose less in vivo toxicity risks to humans, particularly in the context of future development for biomedical applications. To complement the biodegradability data, we have studied the flow behavior of GO sheets into the bloodstream and their interaction with physiological barriers to determine the possible routes of excretion and organ accumulation [13] . Intravenous administration of radiolabelled functionalized GO flakes led to a rapid and significant urinary excretion followed by gradual accumulation in the spleen. Intact hexagonal lattices were detected in the excreted urine, indicating GO clearance. These results provide additional understanding of the kinetic and barrier interactions of thin GO sheets after intravenous administration in mice. Such discoveries have certainly important implications in the future design of graphene-containing materials for different applications, as well as for the assessment of their safety profile.
The activities in the health domain need to continue focusing on a thorough exploration of the biological responses and the toxicity effects of graphenerelated materials by taking into consideration their physicochemical properties and bio-nano-interactions (figure 1).
Four fundamental steps are needed to achieve significant results in the assessment of the safety profile of graphene and 2D materials: (i) to maximize the synergies and coordination among different research approaches; (ii) to map toxicity at different levels (cellular, organ, tissue and environmental); (iii) to compare results to existing carbon-based materials; and (iv) to establish, if required, constraints for safety of use. In a long-term vision, knowledge of graphene and 2D materials' toxicity and environmental risk will favor: (i) the manufacturing, development and applications; (ii) the assessment of technological risk versus risk perception to harmonize technical/social visions; (iii) the development of tools for the governance of key changes in the social landscape for new technology; and (iv) converging technologies, i.e. the integrative process of orienting S&T capabilities towards societal needs. 
